

## EMT4

Product Sheet

Last Updated: 04/06/2021 11:39 AM (EDT)

Author: Darrick Carter



### POC and Institution

POC Name <b>Darrick Carter</b>	POC Title <b>Head of Operations</b>	POC Email <b>darrick.carter@pailifesciences.com</b>
POC Institution <b>PAI Life Sciences</b>	Institution Holds Intellectual Property <b>Yes</b>	Vaccine Ontology Identifier



### Initial Details

Adjuvant Name <b>Emt4</b>	Chemical Nature • <b>Emulsion</b>	Primary Receptor • <b>TLR</b>	Secondary Receptor • <b>TLR4</b>
Mechanism of Action <b>Squalene emulsion plus TLR4</b>	Immune Profile Induced <b>Mixed Th1/Th2</b>	Drug Master File NIAID Support <b>No</b>	Other Features/Characteristics <b>No</b>
Stability Information <b>At least three months at 2-8 degrees C</b>		Storage Information <b>2-8 degrees C</b>	



### In Vivo Use (Preclinical)

Is there an associated publication? <b>No</b>	PubMedID	Disease Area/Pathogen <b>Virus</b>	Parent Organism <b>Severe acute respiratory syndrome-related coronavirus</b>
Antigen <b>Recombinant protein</b>	Immunization Route <b>IM</b>	Readout • <b>Immunogenicity (serology)</b>	Host Species <b>Mouse-C57BL/6</b>
Were PK/Toxicology studies conducted? <b>No</b>			



## Product Grade and Formulation(s)

Product Grade

**Research-grade only**

Formulation(s)

• **Bedside mixing**

Bedside mixing with antigen possible?

**Yes**

Also used in combination adjuvant-formulation?

**No**



## Clinical

Not evaluated in humans yet



## Additional Comments